Introduction {#sec1}
============

The kidney is a specific organ comprising various types of cells. Therefore, kidney cancer may occur in a number of different and specific types that can be characterized by different histologies, different clinical courses and differing responses to a number of varied therapies. To date, the majority of renal cell carcinomas with specified subtypes are the clear cell type (KIRC), followed by papillary (KIRP) and chromophobe (KICH) tumours \[[@cit0001], [@cit0002]\].

The Notch pathway is an evolutionarily conserved signalling mechanism involved in the regulation of proliferation, differentiation, vascular remodelling and angiogenesis in embryonic and adult tissues \[[@cit0003]\]. The canonical Notch pathway is activated by the interaction of DSL ligands (DLL1, DLL3, DLL4, JAG1 and JAG2) and Notch receptors (NOTCH1-NOTCH4) leading to two sequential proteolytic cleavages of the receptors. The first cleavage involves ADAM/TACE metalloprotease, and the remaining portion of Notch is subsequently cleaved by the γ-secretase complex (composed of PSEN1, PSEN2, PEN2, APH1, and nicastrin). A second cleavage is then followed by the release of the Notch intracellular domain (NICD) to the nucleus, where it forms a complex with the DNA binding protein RPBJ and MAML family transcriptional coactivators. The latter induces the expression of Notch downstream effectors, such as transcription factors (TFs), i.e. *HES1* and *HEY1* \[[@cit0004], [@cit0005]\].

Notch plays a key role in kidney development by establishing a proximal tubular epithelial cell fate and cell type specification in the renal collecting system \[[@cit0006]\]. Moreover, it has been proven that aberrant Notch signalling may result in tumourigenesis. For example, a study by Aparicio *et al*. revealed higher *NOTCH1* expression in KICH tissues \[[@cit0007]\]. In turn, reduced Notch signalling was found in KIRP, as demonstrated by gene expression analysis indicating that the Notch downstream effector (*HEY1*) was reduced \[[@cit0008]\]. Nevertheless, as little is known about the prognostic value of Notch members and their influence on disease recurrence, especially in the kidneys, the aim of the present study was to investigate the potential effect of Notch differential expression on disease-free survival (DFS) in KICH, KIRC and KIRP.

Material and methods {#sec2}
====================

We obtained the mRNASeq data of 973 cancer samples (RNA-Seq, level 3 RNASeqV2, RSEM normalized) (data status of Jan 28, 2016) and matched clinical data of the renal carcinoma KIPAN cohort (KICH + KIRC + KIRP) from The Cancer Genome Atlas (TCGA), downloaded from <http://gdac.broadinstitute.org/>. All TCGA samples have been collected, RNA isolated and sequenced according to Institutional Review Board approval of the protocols; see the project website at <http://cancergenome.nih.gov> for more details \[[@cit0009]--[@cit0011]\].

Patients with missing clinical/expression values were excluded from further analyses. Finally, a total of 888 samples were qualified: 66 KICH, 533 KIRC and 289 KIRP patients. The clinical characteristics of the patient cohort are presented in [Table I](#t0001){ref-type="table"}.

###### 

Clinical characteristics of KIRC, KIRP and KICH cohort patients

  Parameter             Total         Males           Females
  --------------------- ------------- --------------- -------------
  KIRC:                                               
   Quantity             533           345             188
   Median age (range)   61 (26--90)   59 (26--90)     63 (29--90)
  Stage:                                              
    I                   267           161             106
    II                  57            43              14
    III                 123           80              43
    IV                  84            59              25
   NA                   --            --              --
  KIRP:                                               
   Quantity             289           213             76
   Median age (range)   62 (37--88)   62 (40--85)     62 (37--88)
  Stage:                                              
    I                   177           132             45
    II                  25            17              8
    III                 53            38              15
    IV                  17            12              5
   NA                   17            14              3
  KICH:                                               
   Quantity             66            39              27
   Median age (range)   50 (17--86)   53.5 (26--78)   46 (17--86)
   Stage:                                             
    I                   22            11              10
    II                  25            13              12
    III                 14            10              4
    IV                  6             5               1
   NA                   --            --              --

NA -- not available.

Previously prepared KICH, KIRC and KIRP data were used to determine the relevance of the expression of 19 Notch signalling pathway members to disease-free survival. The analysis was based on optimal cutoff point determination using the freely available Cutoff Finder web application (<http://molpath.charite.de/cutoff/>). The clinical characteristics defining DFS were as follows: "patient.days_to_last_followup" for survival time and "patient.follow_ups.follow_up.person_neoplasm_cancer_status" for outcome and event.

Statistical analysis {#sec2.1}
--------------------

The significance of the correlation with the survival variable was chosen for optimizing the cutoff point, defined as the point with the most significant split. Additionally, hazard ratios (HRs) including 95% confidence intervals (CI) were calculated \[[@cit0012]\]. Results in the form of Kaplan-Meier survival plots with the *p*-value calculated (log-rank test, *p* \< 0.05) enabled us to split patients into favourable/unfavourable prognosis groups regarding expression of Notch members.

Results {#sec3}
=======

The present study analyses the influence of differential expression of Notch members on DFS in KICH, KIRC and KIRP patients. [Table II](#t0002){ref-type="table"} presents the cutoff points and numbers of patients assigned to groups of low and high expression of Notch members. Contrasting DFS Notch profiles were found across kidney carcinomas. Firstly, lowered expression of *ADAM17* correlated with good prognosis in KICH, KIRC and KIRP (HR = 7.79, *p* = 0.03; HR = 3.98, *p* = 0.051; HR = 11.24, *p* \< 0.001, respectively) ([Figure 1](#f0001){ref-type="fig"}). While lowered expression of *NUMB* was favourable in KICH and KIRP (HR = 6.7, *p* = 0.016; HR = 4.09, *p* \< 0.001, respectively), higher expression was favourable in KIRC (HR = 0.21, *p* = 0.017) ([Figure 1](#f0001){ref-type="fig"}). In contrast, while high *PSEN2* expression correlated with good prognosis in KICH and KIRP (HR = 0.2, *p* = 0.048; HR \< 0.001, *p* = 0.023, respectively), its lowered expression was favourable in KICH (HR = 2.81, *p* \< 0.001) ([Figure 1](#f0001){ref-type="fig"}). Lowered expression of the *DLL4*, *HEY1*, *JAG2*, *NOTCH1*, *NOTCH3* and *NOTCH4* genes was favourable in KIRC and KIRP, while higher expression of *APH1B* was favourable in KIRC and KIRP (HR = 0.53, *p* = 0.028; HR = 0.15, *p* \< 0.001, respectively). *HES4* was found to differentiate between KICH and KIRC, as its higher expression correlated with good prognosis in KICH while its lowered expression was favourable in KIRC (HR = 0.11, *p* = 0.015; HR = 2.42, *p* \< 0.001, respectively). Finally, *ADAM10*, *HES1* and *PSEN1* were significant for DFS in KIRC, *HES5* and *JAG1* in KIRP and *NOTCH2* in KICH ([Table II](#t0002){ref-type="table"}).

###### 

Statistics for DFS analysis

  Gene        Cut-off   Number of patients in group   HR    *P*-value   
  ----------- --------- ----------------------------- ----- ----------- ----------
  KICH:                                                                 
   *ADAM17*   290.9     40                            26    7.79        0.03
   *HES4*     14.17     21                            45    0.11        0.015
   *NOTCH2*   339.9     33                            33    \> 100      0.011
   *NUMB*     524.1     19                            47    6.7         0.016
   *PSEN2*    2729      52                            14    0.2         0.048
  KIRC:                                                                 
   *ADAM10*   4152      513                           20    5.54        0.0017
   *ADAM17*   963.5     499                           34    3.98        0.0051
   *APH1B*    460.7     219                           314   0.53        0.028
   *DLL4*     6186      521                           12    6.36        \< 0.001
   *HES1*     3005      512                           21    2.2         \< 0.001
   *HES4*     230.7     458                           75    2.42        0.0064
   *HEY1*     1072      517                           16    4.83        0.001
   *JAG2*     2251      517                           16    3.64        0.022
   *NOTCH1*   800.4     63                            470   6.05        0.043
   *NOTCH3*   6697      276                           257   1.77        0.051
   *NOTCH4*   7208      518                           15    4.38        0.0074
   *NUMB*     2979      461                           72    0.21        0.017
   *PSEN1*    1534      215                           318   0.44        0.0051
   *PSEN2*    407.2     261                           272   2.81        \< 0.001
  KIRP:                                                                 
   *ADAM17*   875.4     271                           18    11.24       \< 0.001
   *APH1B*    131.1     16                            273   0.15        \< 0.001
   *DLL4*     518       273                           16    5.45        0.0026
   *HES5*     3.4       258                           31    6.78        \< 0.001
   *HEY1*     46.53     165                           124   4.17        0.0017
   *JAG1*     1049      65                            224   \> 100      0.01
   *JAG2*     642.9     272                           14    3.27        0.047
   *NOTCH1*   1504      269                           20    4.05        0.0072
   *NOTCH3*   1237      231                           59    3.78        0.0016
   *NOTCH4*   599.4     265                           24    3.98        0.0026
   *NUMB*     3354      278                           11    4.09        0.0079
   *PSEN2*    542.1     224                           65    \< 0.001    0.023

We defined "low expression" as the expression values below and "high expression" as the expression values above the determined cut-off.
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Discussion {#sec4}
==========

Renal cell carcinoma (RCC), the most common tumour of the adult kidney, displays heterogeneous histologic characteristics, with the majority of cases being KIRC (70--75%), and the remainder comprising KIRP (about 10 % of cases) and KICH (5%) \[[@cit0013]\]. Despite recent progress, new biomarkers and therapeutic targets of renal carcinoma need to be established to overcome the resistance of kidney cancer to various kinds of therapy. The aim of the present study was to evaluate the prognostic effect of the expression of Notch pathway members on DFS in renal carcinoma. Initially, although the effect of 19 genes involved in the Notch pathway were studied, only three of them were found to be significantly associated with a tumour relapse prognosis in all three subtypes ([Table II](#t0002){ref-type="table"}).

*ADAM17* has been found to play a causative role in the development and progression of many cancers and may participate in the tumorigenesis of renal cancer. It has been reported that *ADAM17* mRNA was highly expressed in renal carcinoma \[[@cit0014]\] and its level correlated positively with tumour stage \[[@cit0015]\]. Furthermore, it has been identified that *ADAM17* is frequently expressed in metastatic KIRC and in localized KIRC, and importantly, high expression of *ADAM17* was associated with reduced progression-free survival in patients with KIRC \[[@cit0016]\]. Our present findings indicate that lowered expression of *ADAM17* was correlated with favourable DFS prognosis in all three subtypes of renal carcinoma.

NUMB is an evolutionarily conserved protein that controls multiple development processes such as asymmetric cell division, cell fate choice, cellular adhesion and cell migration. Studies have shown that NUMB-dependent events play an important role in various tumours \[[@cit0017]\]. Sima *et al.* demonstrated that *NUMB* has suppressive potential on the KIRC cell lines 786-0, Caki-1 and Caki-2, and that NUMB protein expression was decreased in the KIRC cell compared with control cells (*p* \< 0.001). In addition, ectopic *NUMB* expression inhibited proliferation, migration and invasion, and this effect may be caused by the downregulation of cyclin D1 or *MMP-9* \[[@cit0018]\]. As expected, a favourable DFS prognosis was found to be associated with elevated expression of *NUMB* in KIRC, which would confirm its suppressive character. Surprisingly, high *NUMB* expression turned out to be significantly correlated with poorer patient prognosis in KICH and KIRP. Together, these findings may indicate that *NUMB* plays a binary role in tumorigenesis: as a suppressor in KIRC and an oncogene in KICH and KIRP.

Presenilin 2 (PSEN2) is a member of the γ-secretase complex, a multi-subunit protease complex involved in intramembrane proteolysis of NOTCH extracellular truncation (NEXT) \[[@cit0005]\]. Mutations in the PSEN2 protein have been widely reported in Alzheimer's disease and many other dementia-associated disorders, but its function in renal cancer remains unclear \[[@cit0019]\]. Our findings show, for the first time, that elevated expression of *PSEN2* has a favourable effect in KICH and KIRP patients, while lowered *PSEN2* expression correlated with better prognosis in KIRC. These data suggest that conversely to *NUMB*, *PSEN2* may possibly function as a tumour suppressor in KICH and KIRP, and as an oncogene in KIRC. Differences in the favourable and unfavourable expression of *NUMB* and *PSEN2* in KIRC, KIRP and KIRP could serve as predictive factors distinguishing the KIRC subtype from two other types of renal cancer.

In addition to *ADAM17*, *NUMB* and *PSEN2*, which are significantly correlated with all types of renal cancer examined in our study, several members of the Notch pathway were associated with specific subtypes. Precisely, better prognosis in KIRC is characterized by low expression of *ADAM10* and *HES1* and high expression of *PSEN1*. Decreased expression of *HES5* and *JAG1* indicates better prognosis for KIRP patients and lowered expression of *NOTCH2* for KICH patients. The data would seem to suggest that some of the Notch pathway members are uniquely associated with particular subtypes of renal cancer.

In conclusion, our findings indicate that the expression profiles of Notch pathway members have a significant influence on DFS in renal carcinoma. As *NUMB* and *PSEN2* have contrasting effects on KIRC, KIRP and KICH, they could serve as prediction factors distinguishing these three subtypes. Moreover, the expression of particular genes may be used to predict the prognosis of relapse of the disease in patients with each subtype of renal cancer. Taken together, our results suggest that members of the Notch signalling pathway have great predictive value and they may serve as novel prognostic biomarkers in KIRC, KIRP and KICH; however, more studies are needed to confirm our results.
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